Treatment-emergent adverse event rates were 10% (2×), 15% (3×), and 10% (placebo); all were Grade 1 injection site erythema or transient pyrexia, except for a single Grade 2 ALT/AST elevation (2.6 × ULN) that resolved spontaneously. This evidence concerns the gene GPT and Fever.